[EN] ROR-GAMMA INHIBITORS<br/>[FR] INHIBITEURS DE ROR-GAMMA
申请人:GLAXOSMITHKLINE IP DEV LTD
公开号:WO2019063748A1
公开(公告)日:2019-04-04
The present invention relates to compounds of formula I and pharmaceutical compositions comprising compounds of formula I. Compounds of Formula I are useful in treatment of inflammatory, metabolic or autoimmune diseases which are mediated by RORy.
Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same
申请人:Liu Haiyan
公开号:US20110009628A1
公开(公告)日:2011-01-13
The present technology relates to compounds of Formulas I-VI and methods of making and using such compounds. Methods of use include prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Compounds disclosed herein also increase HDL-C, lower total cholesterol, LDL-cholesterol, and triglycerides and increase hepatic LDL receptor expression, inhibit PCSK9 expression, and activate AMP-activated protein kinase.
Pd-Catalyzed α-Arylation of Trimethylsilyl Enolates of α,α-Difluoroacetamides
作者:Shaozhong Ge、Sophie I. Arlow、Michael G. Mormino、John F. Hartwig
DOI:10.1021/ja508590k
日期:2014.10.15
ilyl)acetamides with aryl and heteroaryl bromides catalyzed by an air- and moisture-stable palladacyclic complex containing P(t-Bu)2Cy as ligand. A broad range of electronically varied aryl and heteroaryl bromides underwent this transformation to afford α-aryl-α,α-difluoroacetamides in high yields. Due to the electrophilicity of the fluorinated amide, this palladium-catalyzed cross-coupling reaction
[EN] THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS<br/>[FR] THIÉNOPYRIDINE CARBOXAMIDES UTILISÉS COMME INHIBITEURS DE PROTÉASE SPÉCIFIQUE DE L'UBIQUITINE
申请人:FORMA THERAPEUTICS INC
公开号:WO2017139778A1
公开(公告)日:2017-08-17
The disclosure relates to inhibitors of USP28 and/or USP25 useful in the treatment of cancers, inflammation, autoimmune diseases, and infectious diseases, having the Formula (I), where R1, R2, R3, R4, R5, R5', R6, R7, X, m, and n are described herein.
[EN] CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED BY TERTIARY HYDROXY GROUPS AS PI3K-GAMMA INHIBITORS<br/>[FR] DÉRIVÉS D'IMIDAZOLE CONDENSÉS, SUBSTITUÉS PAR DES GROUPES HYDROXY TERTIAIRES, UTILISÉS COMME INHIBITEURS DE PI3K-GAMMA
申请人:INCYTE CORP
公开号:WO2019079469A1
公开(公告)日:2019-04-25
This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-y which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.